Cumberland Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Cumberland Pharmaceuticals (CPIX) Reports Q4 Loss of $0.05
March 7, 2017 4:34 PM ESTCumberland Pharmaceuticals (NASDAQ: CPIX) reported Q4 EPS of ($0.05), versus $0.01 reported last year. Revenue for the quarter came in at $9 million, versus $7.89 million reported last year.
For earnings history and earnings-related data on Cumberland Pharmaceuticals (CPIX) click here.
... More